keyword
MENU ▼
Read by QxMD icon Read
search

gastric cancer chemotherapy

keyword
https://www.readbyqxmd.com/read/29345284/quantitative-proteomics-analysis-of-the-role-of-tetraspanin-8-in-the-drug-resistance-of-gastric-cancer
#1
Lan Li, Daping Yang, Dejun Cui, Yu Li, Zhao Nie, Jinglin Wang, Li Liang
Gastric cancer, due to its high incidence rate, is the second leading cause of cancer-related mortality worldwide. Chemotherapy is an important component of the multimodal treatment for gastric cancer; however, a significant impediment to successful treatment is multidrug resistance (MDR) in patients with gastric cancer. In the present study, the protein profiles of the MDR cell line, SGC7901/DDP, and its parental cell line, SGC7901, were comparatively analyzed through an iTRAQ-based quantitative proteomics technique...
February 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29344235/metronomic-chemotherapy-remodel-cancer-associated-fibroblasts-to-decrease-chemoresistance-of-gastric-cancer-in-nude-mice
#2
Chao Wang, Wenqi Xi, Jinling Jiang, Jun Ji, Yingyan Yu, Zhenggang Zhu, Jun Zhang
The present study aimed to evaluate whether capecitabine or 5-fluorouracil (5-Fu) chemotherapy with the metronomic pattern may cause significant chemoresistance compared with the traditional pattern, and whether CAFs are involved in drug resistance. SGC-7901 cells were subcutaneously injected into the nude mice, and the mice were divided into five groups: The control group, intraperitoneally injected with normal saline; the 5-Fu conventional dose group [5-Fu maximum tolerated dose (MTD) group], intraperitoneally injected with 50 mg/kg, twice per week for 2 weeks, with an 1-week discontinuation for 6 weeks; the capecitabine conventional dose group (capecitabine MTD group), intragastric 500 mg/kg, twice per week for 2 weeks, with a 1-week discontinuation for 6 weeks; the 5-Fu metronomic group [5-Fu low-dose metronomic (LDM) group], intraperitoneally injected with 15 mg/kg, twice a week for 6 weeks; and the capecitabine metronomic group (capecitabine LDM group), intragastric administration at 200 mg/kg, twice a week for 6 weeks...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29344144/melanoma-differentiation-associated-gene-7-suppresses-human-gastric-cancer-cell-invasion-and-migration
#3
Li Xu, Jinyan Chen, Wei Lin, Jinkun Chen, Zhiwei Chen
Gastric cancer is one of the most common types of cancer in the world. Patients with gastric cancer often respond poorly to conventional chemotherapies, therefore more comprehensive therapy is required. Melanoma differentiation-associated gene-7 (MDA-7), also termed interleukin-24, is a potent tumor suppressor gene. Numerous studies have demonstrated that MDA-7 suppresses the growth and induces the apoptosis of cancer cells. In the present study, the MDA-7 gene was transfected into human gastric cancer AGS cells using adenovirus...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29340022/a-functional-polymorphism-of-ssbp1-gene-predicts-prognosis-and-response-to-chemotherapy-in-resected-gastric-cancer-patients
#4
Qiuchen Li, Falin Qu, Renli Li, Xianli He, Yulong Zhai, Weigang Chen, Yong Zheng
Growing evidence has indicated that single-stranded DNA-binding proteins 1 (SSBP1) is involved in tumor initiation and progression. However, effects of single nucleotide polymorphisms (SNPs) in SSBP1 gene on gastric cancer (GC) prognosis are still unknown. In present study, two functional SNPs from SSBP1 were selected and genotyped in a large cohorts of 1030 resected GC patients (326 in the training set, 704 in the validation set) to explore the association of SNPs with patients' survival. The rs6976500 G allele (CG/GG) genotypes were found significantly associated with both worse overall survival (OS) and recurrence-free survival (RFS) in the training and the independent validation set when compared to C allele genotype, which reaching a more robust statistical significance in the pooled analysis...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29337065/downregulated-circular-rna-hsa_circ_0001649-regulates-proliferation-migration-and-invasion-in-cholangiocarcinoma-cells
#5
Yi Xu, Yue Yao, Xiangyu Zhong, Kaiming Leng, Wei Qin, Lijun Qu, Yunfu Cui, Xingming Jiang
Cholangiocarcinoma (CCA) is one of the most aggressive malignancies with increasing worldwide incidence and is characterized by unfavorable prognosis due to its early invasive characteristics and poor response to chemotherapy or radiotherapy. Accumulating evidence has indicated that aberrantly expressed circular RNAs (circRNAs) are involved in cancer development and progression. However, their clinical values and biological roles in CCA remain unclear. Hsa_circ_0001649, a novel cancer-related circRNA, has been previously reported to be downregulated in hepatocellular carcinoma and gastric cancer...
January 11, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29336669/first-line-treatment-of-apatinib-in-elderly-patient-of-advanced-gastric-carcinoma-a-case-report-of-ngs-driven-targeted-therapy
#6
Yan Yang, Wuqiong Zhang, Jinghao Yao, Jing Liu, Shukui Qin, Qiong Wu
Gastric carcinoma (GC) is a common gastrointestinal malignancy with high incidence and mortality worldwide, and most patients are diagnosed in the late stages of disease. Palliative chemotherapy provides a survival benefit for patients with inoperable advanced GC. However, elderly patients who are unable to tolerate chemotherapy had worse prognosis due to lack of effective treatment. Herein we reported a Chinese elderly GC patient using next generation sequencing (NGS)-based tumor DNA analysis. Valuable gene variants of vascular endothelial growth factor (VEGF) A gene amplification were detected...
January 16, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29333068/nab-paclitaxel-as-second-line-treatment-in-advanced-gastric-cancer-a-multicenter-phase-ii-study-of-the-hellenic-oncology-research-group
#7
Panagiotis Katsaounis, Athanasios Kotsakis, Nikolaos Kentepozidis, Aris Polyzos, Marios Bakogeorgos, Filippos Koinis, Lambros Vamvakas, Nikolaos Vardakis, Kostas Kalbakis, Ioannis Boukovinas, Ioannis I Varthalitis, Efthimios Prinarakis, Vassilis Georgoulias, John Souglakos
Background: This study evaluated the safety and efficacy of nab-paclitaxel as second-line treatment in patients with advanced gastric adenocarcinoma. Methods: Thirty-nine pretreated patients [33 with taxane-based regimens (docetaxel, cisplatin, and fluorouracil)] and 6 with combination of fluoropyrimidines plus cisplatin with locally advanced inoperable and metastatic gastric and gastroesophageal junction adenocarcinoma were treated with weekly nab-paclitaxel (150 mg/m2 d1, d8, d15 in cycles of 28 days)...
January 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29331492/prognostic-value-of-the-expression-of-dna-repair-related-biomarkers-mediated-by-alcohol-in-gastric-cancer-patients
#8
Yiyin Zhang, Hongyang Wu, Feng Yang, Jie Ning, Min Li, Chenchen Zhao, Shuping Zhong, Kangsheng Gu, Hua Wang
Alcohol consumption likely induces gastric carcinogenesis through deregulation of RNA polymerase (Pol) III genes and oxidative damage. Transcription factor IIB-related factor 1 (BRF1) overexpression alleviates RNA Pol III transcription inhibition through breast cancer susceptibility gene 1 (BRCA1). Myeloperoxidase (MPO) involvement in cancer is induced by alcohol-mediated oxidative damage. BRCA1/2 and MPO play key roles in DNA repair. BRCA1 and BRCA2 exert different roles in homologous recombination repair...
January 5, 2018: American Journal of Pathology
https://www.readbyqxmd.com/read/29330298/stemness-is-enhanced-in-gastric-cancer-by-a-set-pp2a-e2f1-axis
#9
Shuhei Enjoji, Ryotaro Yabe, Shunya Tsuji, Kazuhiro Yoshimura, Hideyoshi Kawasaki, Masashi Sakurai, Yusuke Sakai, Hiroko Takenouchi, Shigefumi Yoshino, Shoichi Hazama, Hiroaki Nagano, Hiroko Oshima, Masanobu Oshima, Michael P Vitek, Tetsuya Matsuura, Yoshitaka Hippo, Tatsuya Usui, Takashi Ohama, Koichi Sato
Gastric cancer is the fifth most common malignancy and the third leading cause of cancer-related deaths worldwide. Chemotherapies against gastric cancer often fail, with cancer recurrence due potentially to the persistence of cancer stem cells. This unique subpopulation of cells in tumors possess the ability to self-renew and de-differentiate. These cancer stem cells are critical for initiation, maintenance, metastasis, and relapse of cancers; however, the molecular mechanisms supporting cancer stemness remain largely unknown...
January 12, 2018: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/29329964/is-quality-of-registry-treatment-data-related-to-registrar-experience-and-workload-a-study-of-taiwan-cancer-registry-data
#10
Chin-Ying Cheng, Chun-Ju Chiang, Cheng-Hsing Hsieh, You-Kang Chang, Mei-Shu Lai
BACKGROUND: Although cancer treatment information has been collected through the Cancer Registry system in Taiwan for more than 10 years, the accuracy of such data has never been evaluated. This study examined the accuracy rate between registrar experience and on-site chart review for the first course of cancer treatment. METHODS: In this retrospective chart review study, 392 randomly selected medical records from 14 hospitals were re-abstracted by experienced abstractors...
January 10, 2018: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/29329598/treatment-outcome-of-anti-angiogenesis-through-vegf-pathway-in-the-management-of-gastric-cancer-a-systematic-review-of-phase-ii-and-iii-clinical-trials
#11
Brian Mawalla, Xianglin Yuan, Xiaoxiao Luo, Phillip L Chalya
OBJECTIVES: Advanced gastric cancer poses a therapeutic challenge worldwide. In randomised clinical trials, anti-VEGF has been reported as an essential agent for the treatment of advanced gastric cancer. This review aims at assessing the treatment outcome of anti-angiogenesis therapy through the VEGF pathway in the management of patients with advanced gastric cancer. RESULTS: During this review, 38 clinical trials were identified. Of these, 30 clinical trials were excluded, leaving eight trials of phase II and III...
January 12, 2018: BMC Research Notes
https://www.readbyqxmd.com/read/29328433/peiminine-serves-as-an-adriamycin-chemosensitizer-in-gastric-cancer-by-modulating-the-egfr-fak-pathway
#12
Qianqian Tang, Yunfei Wang, Lanjing Ma, Meiling Ding, Tingyu Li, Yongzhan Nie, Zhengyi Gu
Gastric cancer (GC) is one of the most common malignancies of the digestive tract. Adriamycin (ADR) has been widely utilized in various chemotherapy regimens for treating GC, yet its long-term application may increase drug resistance resulting in treatment failure. Increasing evidence shows that bioactive natural products can be used as chemotherapeutic sensitizers that can significantly improve chemotherapy sensitivity. Peiminine (PMI) is a biologically active component extracted from Fritillaria walujewii Regel...
January 3, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29328428/regulation-of-drug-resistance-and-metastasis-of-gastric-cancer-cells-via-the-microrna647-ank2-axis
#13
Wenlong Cao, Weiyuan Wei, Zexu Zhan, Dongyi Xie, Yubo Xie, Qiang Xiao
Due to a lack of effective methods for early diagnosis, the majority of patients with gastric cancer (GC) are diagnosed during the late stages of the disease, which are often accompanied by metastasis. For these patients, despite being considered an important therapeutic modality in the treatment of cancer, chemotherapy is usually not effective due to multidrug resistance (MDR). The expression levels of MDR/metastasis‑associated genes are regulated by numerous microRNAs (miRNAs/miRs). The expression of miR-647 in GC tissues and SGC7901/VCR cell line (drug resistance to vincristine) was detected by qRT-PCR...
January 11, 2018: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/29312573/improvement-of-anti-cancer-drug-efficacy-via-thermosensitive-hydrogel-in-peritoneal-carcinomatosis-in-gastric-cancer
#14
Tae-Su Han, Keun Hur, Boram Choi, Ji-Yeon Lee, Sun-Ju Byeon, Jimin Min, Jieun Yu, Jung-Kyo Cho, Jimin Hong, Hyuk-Joon Lee, Seong-Ho Kong, Woo-Ho Kim, Kazuyoshi Yanagihara, Soo-Chang Song, Han-Kwang Yang
Peritoneal carcinomatosis (PC) of gastric origin has a poor prognosis with short survival due to lack of effective therapeutic modalities. Here, we evaluated the therapeutic efficacy of an injectable thermosensitive poly (organophosphazene) (PPZ) hydrogel with docetaxel (DTX-gel) to develop an effective therapeutic agent for patient with PC. Three days after inoculation of highly metastatic 44As3Luc cells into peritoneal cavity, the mice were intravenously or intraperitoneally administered with docetaxel alone (DTX-sol IV or IP), and intraperitoneally injected with DTX-gel...
December 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29310611/study-protocol-of-a-phase-ii-clinical-trial-kscc1501a-examining-oxaliplatin%C3%A2-%C3%A2-s-1-for-treatment-of-her2-negative-advanced-recurrent-gastric-cancer-previously-untreated-with-chemotherapy
#15
Hiroshi Saeki, Yasunori Emi, Eiji Oki, Shoji Tokunaga, Yoshihiro Kakeji, Yoshito Akagi, Hideo Baba, Eishi Baba, Yoshihiko Maehara
BACKGROUND: Oxaliplatin + S-1 is a recognized treatment regimen in Japan, but there are no Japanese clinical data on an oxaliplatin dose of 130 mg/m2. The current research involves a single-arm, prospective, phase II clinical trial to examine the efficacy and safety of oxaliplatin + S-1 with an oxaliplatin dose of 130 mg/m2 to treat HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy in Japan. METHODS/DESIGN: The primary endpoint of this trial will be the response rate, and the secondary endpoints will be the safety profile of oxaliplatin + S-1, progression-free survival, the response rate in subjects under the age of 75, overall survival, time to treatment failure, duration of treatment, time to failure of strategy, and dose intensity...
January 8, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29302921/isolated-breast-metastasis-from-gastric-cancer-in-a-male-patient
#16
Hirokazu Kubo, Tetsuya Shimizu, Hitoshi Sekido, Goro Matsuda, Kazuhisa Takeda, Akira Watanabe, Risa Sakamoto, Yuji Yamamoto, Junya Toyoda, Hitoshi Niino
A 72-year-old man underwent total gastrectomy for gastric cancer (por2, T3, N2, Stage IIIA). Eleven courses of postoperative chemotherapy with TS-1 (tegafur/gimeracil/oteracil) were administered. Five months after surgery, the serum carcinoembryonic antigen value was slightly elevated. However, computed tomography did not reveal any metastatic lesions in other organs. Two years after surgery, the patient felt a mass in the left mammary. A 2-cm tumor was palpable in the central portion of the breast. Ultrasonography revealed a hypoechoic tumor, which was Class 3 on aspiration biopsy cytological examination...
January 4, 2018: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/29302191/ercc1-rs3212986-a-c-polymorphism-is-not-associated-with-chemotherapy-treatment-outcomes-in-gastric-cancer-patients-evidence-from-11-publications-in-chinese-populations
#17
Weiwei Tang, Hanjin Wang, Yuemei Wang, Xiaowei Wang
Background: A number of studies have investigated the roles of excision repair cross-complementation group 1 (ERCC1) gene rs3212986 polymorphisms as potential biomarkers in gastric cancer (GC). However, the results were inconsistent. Here, we performed a meta-analysis to explore ERCC1 rs3212986 polymorphisms in the chemotherapy response and clinical outcome of GC. Methods: PubMed, Embase, and Web of Science were searched up to July 28, 2017, for studies on the association between ERCC1 rs3212986 A/C polymorphisms and response to chemotherapy as well as overall survival time of GC...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29302045/mir-200c-inhibits-tgf-%C3%AE-induced-emt-to-restore-trastuzumab-sensitivity-by-targeting-zeb1-and-zeb2-in-gastric-cancer
#18
Xinliang Zhou, Xinyi Men, Riyang Zhao, Jing Han, Zhisong Fan, Yudong Wang, Yalei Lv, Jing Zuo, Lianmei Zhao, Meixiang Sang, Xian-De Liu, Baoen Shan
Gastric cancer is the fifth most common malignancy in the world, with Eastern Asia as one of areas with the highest incidence rates. Trastuzumab, a HER2-targeting antibody, combined with chemotherapy has been successfully employed for the gastric cancer patients with HER2 overexpression/amplification. However, trastuzumab resistance is a major problem in clinical practice. Here we observed that the trastuzumab-resistant gastric cancer cell line NCI-N87/TR expressed high levels of epithelial-mesenchymal transition factors and demonstrated increased migration and invasion capability compared with NCI-N87 cells...
January 4, 2018: Cancer Gene Therapy
https://www.readbyqxmd.com/read/29299372/heated-intraperitoneal-chemotherapy-and-gastrectomy-for-gastric-cancer-in-the-u-s-the-time-is-now
#19
REVIEW
Zachary J Brown, Jonathan M Hernandez, R Taylor Ripley, Jeremy L Davis
Peritoneal metastasis is a common final pathway in patients with gastric adenocarcinoma. Microscopic evidence of early peritoneal dissemination of gastric cancer is present in a substantial proportion of patients presumed to have localized disease. Prognosis is poor even for patients with microscopic and low-volume peritoneal carcinomatosis highlighting the need for a more effective treatment strategy. Treatment of peritoneal carcinomatosis with intraperitoneal chemotherapy has been evaluated in gastric cancer and is associated with improved survival in selected patients...
December 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29299362/tumor-response-evaluation-after-neoadjuvant-chemotherapy-in-locally-advanced-gastric-adenocarcinoma-a-prospective-multi-center-cohort-study
#20
Pietro Achilli, Paolo De Martini, Marco Ceresoli, Giulio M Mari, Andrea Costanzi, Dario Maggioni, Raffaele Pugliese, Giovanni Ferrari
Background: To verify the prognostic value of the pathologic and radiological tumor response after neoadjuvant chemotherapy in the treatment of locally advanced gastric adenocarcinoma. Methods: A total of 67 patients with locally advanced gastric cancer (clinical ≥ T2 or nodal disease and without evidence of distant metastases) underwent perioperative chemotherapy (ECF or ECX regimen) from December 2009 through June 2015 in two surgical units. Histopathological and radiological response to chemotherapy were evaluated by using tumor regression grade (TRG) (Becker's criteria) and volume change assessed by CT...
December 2017: Journal of Gastrointestinal Oncology
keyword
keyword
40929
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"